ADC狂欢属于少数：东曜撤退背后，卡在半路的Biotech如何善终？
可以期待，泛偶联时代，放手一搏的创新药企，仍可能走出一条差异化发展之路。
Time：
2023-05-06 17:01
Author：
xieyijun
抗糖与CGT天作之合？创新争夺战已打响，最快有望2030年前上市
创新终究需要市场买账，广阔的糖尿病市场愿景，对细胞基因治疗来说，可以说是应许之地吗？
Time：
2023-05-06 14:13
Author：
xieyijun
病毒感染已成为公众健康和安全的严重关切，尤其是最近几年的SARS-COV-2病毒让人们更加重视这一领域。
Time：
2023-05-06 13:59
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务